Mk677 vs Tesamorelin: A Research Reference
The practical distance between Mk677 and Tesamorelin shows up first in how much published methodology exists for each.
Compound profiles
Mk677 in the indexed record
The literature on Mk677 is a limited body of work: 39 PubMed-indexed records, alongside 8 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Am J Sports Med, BMJ Case Rep, Exp Physiol, spanning 1998–2026.
- MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism — J Clin Endocrinol Metab, 1998. PMID: 9467534
- Hepatotoxicity induced by MK-677 — BMJ Case Rep, 2025. PMID: 40675653
- LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report — Exp Physiol, 2022. PMID: 36303408
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine — Am J Sports Med, 2026. PMID: 42578445
Tesamorelin in the indexed record
The literature on Tesamorelin is a moderate body of work: 121 PubMed-indexed records, alongside 24 registered studies on ClinicalTrials.gov.
Journals represented in the current index include Ann Pharmacother, BETA, Curr Opin Investig Drugs, spanning 2006–2012.
- Tesamorelin — , 2012. PMID: 31644039
- Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy — Ann Pharmacother, 2012. PMID: 22298602
- Tesamorelin, a human growth hormone releasing factor analogue — Expert Opin Investig Drugs, 2009. PMID: 19243281
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy — Drugs, 2011. PMID: 21668043
How the literature differs
The indexed record is not symmetrical between these two compounds. Tesamorelin carries 82 more indexed records than Mk677, which means published methodology, characterisation data and replication attempts are more readily located for Tesamorelin. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (8 vs 24) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Side-by-side research profile
| Parameter | Mk677 | Tesamorelin |
|---|---|---|
| PubMed indexed records | 39 | 121 |
| Registered studies (ClinicalTrials.gov) | 8 | 24 |
| Literature depth | Emerging | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
Mk677 and Tesamorelin sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for Mk677 describes conditions validated for Mk677: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Tesamorelin without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Verification and documentation
What is in the vial is established by lot-specific analytics, not by label text. HPLC gives purity as a share of total peak area; mass spectrometry confirms the molecular weight matches the intended sequence. Neither substitutes for the other.
Physical handling notes
Both arrive lyophilised. Standard practice keeps the unopened vial at -20°C, protected from light, and defers reconstitution until the point of use. Solution-phase stability is the limiting factor in most protocols, not powder-phase stability.
Repeated freezing and thawing is the most common avoidable source of degradation.
Frequently asked questions
Are Mk677 and Tesamorelin the same compound?
No. They are structurally distinct research compounds with separate literature records — 39 indexed records for Mk677 and 121 for Tesamorelin.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Which of Mk677 or Tesamorelin has more published research?
Tesamorelin, with 121 indexed PubMed records against 39.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Related references
- Tesamorelin — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.